Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways

Ileana-Raluca Pătru1,2, Dimitrie-Ionuț Atasiei1,3, Radu Tudor Ionescu4

  • 1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Insights

Immune checkpoint inhibitors (ICIs) can cause various cardiac issues. This study integrates pathways to explain cardiovascular toxicities, identifying PD-1/PD-L1 as a key hub and suggesting biomarkers for early detection.

Area of Science:

  • Cardiovascular research
  • Immunology
  • Oncology
  • Systems biology

Background:

  • Immune checkpoint inhibitors (ICIs) are a major cancer therapy class with over 100 FDA-approved indications.
  • While preclinical research focused on myocarditis and atherosclerosis, broader cardiovascular toxicities like non-inflammatory left ventricular dysfunction (NILVD), arrhythmias, and vasculitis occur.
  • Existing models rarely connect these diverse cardiovascular immune-related adverse events (irAEs) mechanistically.

Purpose of the Study:

  • To develop a systems-oriented framework linking immune checkpoint pathways to cardiovascular cell types, molecular pathways, and biomarkers.
  • To elucidate the mechanistic basis of diverse cardiovascular irAEs associated with ICIs.
  • To identify potential biomarkers for predicting and monitoring ICI-induced cardiac toxicity.

Main Methods:

  • Systematic literature search of PubMed, Scopus, and Web of Science for ICI and cardiovascular irAE mechanisms.
  • AI-assisted semantic clustering to organize and analyze the retrieved literature.
  • Integration of findings into a mechanistic framework mapping checkpoint pathways to cardiac and vascular processes.

Main Results:

  • The PD-1/PD-L1 pathway is identified as a central hub connecting T-cell activation, endothelial injury, myocardial damage, and vascular inflammation.
  • A shared immune core (checkpoint pathways, cytokine signaling, leukocyte trafficking) underlies various irAE phenotypes, with specific mediators influencing injury type (myocarditis, NILVD, etc.).
  • KEGG analyses revealed enrichment in T-cell receptor signaling, Th17 differentiation, JAK-STAT signaling, and lipid/atherosclerosis pathways.
  • Candidate biomarkers include troponin, IL-6, CXCL9/10/13, S100 proteins, ROCK2, HLA-linked signals, and T-cell receptor clonality.

Conclusions:

  • The developed framework provides a map for understanding ICI-related cardiac toxicities and generating new hypotheses.
  • PD-1/PD-L1 blockade plays a critical role in mediating cardiovascular irAEs through shared and phenotype-specific mechanisms.
  • AI-assisted clustering offers a complementary approach for literature organization in complex biological research.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...